Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oneness Biotech Co Ltd

http://www.onenessbio.com.tw/en/

Latest From Oneness Biotech Co Ltd

Leo Pharma Strengthens Dermatology Position With Second Eczema Win

The company reported positive topline results from a second trial of its topical pan-JAK inhibitor, delgocitinib, in chronic hand eczema.

Clinical Trials Business Strategies

FDA Thwarts Leo Pharma's US Launch Plans For Tralokinumab

A week after getting the thumbs-up from the CHMP for tralokinumab, the Denmark-based dermatology specialist has been hit by a complete response letter from US regulators requesting more data about a device component of the IL-13 inhibitor.

Dermatology Complete Response Letters

Leo's Tralokinumab Poised For US Launch In 2021

The dermatology specialist said a BLA for the IL-13 blocker has been accepted by the US FDA for the treatment of atopic dermatitis.

Dermatology Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • OTC, Consumer
UsernamePublicRestriction

Register